{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:04:21Z","timestamp":1782601461418,"version":"3.54.5"},"reference-count":37,"publisher":"Impact Journals, LLC","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,3,14]]},"DOI":"10.18632\/oncotarget.14935","type":"journal-article","created":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T20:20:36Z","timestamp":1485980436000},"page":"18021-18030","source":"Crossref","is-referenced-by-count":34,"title":["High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers"],"prefix":"10.18632","volume":"8","author":[{"given":"Yih-Leong","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan"},{"name":"Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei 10002, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan"},{"name":"Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei 10002, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Lin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Tu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan"},{"name":"Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei 10002, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan-Chyr","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan"},{"name":"Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei 10002, Taiwan"},{"name":"National Taiwan University, Taipei 10617, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,2,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/annonc\/mdl498","article-title":"Estimates of the cancer incidence and mortality in Europe in 2006","volume":"18","author":"Boyle","year":"2007","journal-title":"Ann Oncol"},{"key":"2","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/ng.2405","article-title":"Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer","volume":"44","author":"Bhatt","year":"2012","journal-title":"Nature Genetics"},{"key":"3","doi-asserted-by":"crossref","first-page":"V120","DOI":"10.1093\/annonc\/mdq172","article-title":"on behalf of the ESMO Guidelines Working Group. Small-cell-lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up","volume":"21","author":"Felip","year":"2010","journal-title":"Ann Oncol"},{"key":"4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Chen","year":"2002","journal-title":"Nat Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejso.2015.01.020","article-title":"The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis","volume":"41","author":"Liu","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2016.03.012","article-title":"High co-expression of PD-L1 and HIF-1\u03b1 correlates with tumour necrosis in pulmonary pleomorphic carcinoma","volume":"60","author":"Yang","year":"2016","journal-title":"Eur J Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Bhatia","year":"2012","journal-title":"N Engl J Med"},{"key":"8","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Antonia","year":"2012","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Anders","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/modpathol.2011.150","article-title":"Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas","volume":"25","author":"Travis","year":"2012","journal-title":"Mod Pathol"},{"key":"11","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up","volume":"66","author":"Cheville","year":"2006","journal-title":"Cancer Res"},{"key":"12","first-page":"127ra37","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Chen","year":"2012","journal-title":"Sci Transl Med"},{"key":"13","first-page":"533","article-title":"Novel therapies in small cell lung cancer","volume":"4","author":"Jalal","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"14","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1016\/S0959-8049(11)70173-3","article-title":"Small cell lung cancer: new clinical recommendations and current status of biomarker assessment","volume":"47","author":"Le P\u00e9choux","year":"2011","journal-title":"Eur J Cancer"},{"key":"15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Lawrence","year":"2014","journal-title":"Nature"},{"key":"16","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.ejca.2014.01.018","article-title":"Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes","volume":"50","author":"Yang","year":"2014","journal-title":"Eur J Cancer"},{"key":"17","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.oraloncology.2015.08.011","article-title":"Associations among pretreatment tumor necrosis and the expression of HIF-1\u03b1 and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof","volume":"51","author":"Chang","year":"2015","journal-title":"Oral Oncol"},{"key":"18","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/JTO.0b013e318292be18","article-title":"Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1)","volume":"8","author":"Schalper","year":"2013","journal-title":"J Thorac Oncol"},{"key":"19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.lungcan.2015.03.017","article-title":"PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy","volume":"88","author":"Yang","year":"2015","journal-title":"Lung Cancer"},{"key":"20","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/JTO.0000000000000414","article-title":"Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer","volume":"10","author":"Hoshino","year":"2015","journal-title":"J Thorac Oncol"},{"key":"21","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejca.2014.12.006","article-title":"PD-L1 expression in small cell neuroendocrine carcinomas","volume":"51","author":"Buettner","year":"2015","journal-title":"Eur J Cancer"},{"key":"22","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.ejca.2015.06.003","article-title":"PD-L1 expression in small cell lung cancer","volume":"51","author":"Madan","year":"2015","journal-title":"Eur J Cancer"},{"key":"23","doi-asserted-by":"crossref","first-page":"e65821","DOI":"10.1371\/journal.pone.0065821","article-title":"PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"24","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Arrieta","year":"2015","journal-title":"N Engl J Med"},{"key":"25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Gainor","year":"2015","journal-title":"N Engl J Med"},{"key":"26","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Hegde","year":"2014","journal-title":"Nature"},{"key":"27","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3892\/ol.2014.2356","article-title":"Role of programmed death ligands in effective T-cell interactions in extranodal natural killer\/T-cell lymphoma","volume":"8","author":"Zhang","year":"2014","journal-title":"Oncol Lett"},{"key":"28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2015.12.033","article-title":"Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma","volume":"57","author":"Yang","year":"2016","journal-title":"Eur J Cancer"},{"key":"29","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s12026-015-8662-0","article-title":"Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer","volume":"62","author":"Long","year":"2015","journal-title":"Immunol Res"},{"key":"30","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/030089161209800612","article-title":"Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: A 5-year-follow-up study","volume":"98","author":"Huang","year":"2012","journal-title":"Tumori"},{"key":"31","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-04-1469","article-title":"Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer","volume":"11","author":"Yagita","year":"2005","journal-title":"Clin Cancer Res"},{"key":"32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.acthis.2006.01.003","article-title":"Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance","volume":"108","author":"Xu","year":"2006","journal-title":"Acta Histochem"},{"key":"33","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","article-title":"Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer","volume":"13","author":"Nakajima","year":"2007","journal-title":"Clin Cancer Res"},{"key":"34","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1078-0432.CCR-08-1608","article-title":"Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma","volume":"15","author":"Fan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"35","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Fujii","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"36","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1158\/1078-0432.CCR-13-2702","article-title":"situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas","volume":"20","author":"In","year":"2014","journal-title":"Clin Cancer Res"},{"key":"37","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.24899","article-title":"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma","volume":"116","author":"Tokura","year":"2010","journal-title":"Cancer"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14935","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T17:10:18Z","timestamp":1589130618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,1]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,3,14]]}},"alternative-id":["14935","28152514"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.14935","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,1]]}}}